Novartis is committed to medical research and is the second highest investor in R&D worldwide. As a result, for the third consecutive time, Novartis has been recognised for having the industry-leading pipeline with over 138 projects in clinical development. During 2012, medicines and vaccines from Novartis were used to treat and protect more than 1.2 billion people worldwide.
In partnership with the World Health Organisation (WHO), Novartis has given, 340 million antimalarial treatments supplied without profit, helping to save an estimated 850,000 lives. Novartis is also committed to providing free leprosy treatments worldwide, curing almost five million patients.
Novartis in Ireland
Over 1,200 people are employed in two manufacturing plants in Cork and commercial operations in Dublin. Novartis is committed to R&D in Ireland. In 2012 €4m was invested in R&D and over the last three years, seventeen clinical trials have been conducted, in areas such as Oncology, Respiratory, Ophthalmology and Neurology.
Located in Model Farm Road, Cork, Alcon (a Novartis company) manufactures the world’s leading intraocular lens for various countries around the globe. Alcon’s AcrySof lenses are implanted in six of every ten cataract surgery patients worldwide.
Novartis is also addressing the unmet needs of COPD patients through an emerging portfolio of pioneering medicines and (made in Ringaskiddy, Cork) devices that may help transform treatment outcomes for people with COPD (chronic obstructive pulmonary disease).
Find out more about the work of Novartis at